Julio Rosenstock, MD, FACE, Presents Promising Data on Oral Semaglutide’s Effect on HbA1c for Adults with Prediabetes

Julio Rosenstock, MD, FACE, Principal Investigator at Velocity and the leader of the Diabetes and Obesity CARE Council, unveiled data suggesting a potential breakthrough for adults with prediabetes. When administered oral semaglutide, trial participants achieved normoglycemia at 68 weeks.

Dr. Rosenstock commented, “Those people who participated in the OASIS 1 trial with prediabetes who received oral semaglutide experienced more HbA1c normalization and none progressed to type 2 diabetes.” Furthermore, the same group of adults with prediabetes lost an impressive 14.4% of their body weight by week 68, compared to 2.5% weight loss in the placebo group.

Read more: https://www.healio.com/news/endocrinology/20231020/most-adults-with-prediabetes-achieve-normoglycemia-at-68-weeks-with-oral-semaglutide

Posted in

Quality. Continuity. Velocity.